| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZDHHC12 |
| Uniprot No | Q96GR4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-322 aa |
| 活性数据 | MAPWALLSPGVLVRTGHTVLTWGITLVLFLHDTDKSADELLATHSHSWNQHLQAFAQPGTHFPTSNCTPTPPTPVLPGPASLCSPASPELRQWEEQGELLLPLTFLLLVLGSLLLYLAVSLMDPGYVNVQPQPQEELKEEQTAMVPPAIPLRRCRYCLVLQPLRARHCRECRRCVRRYDHHCPWMENCVGERNHPLFVVYLALQLVVLLWGLYLAWSGLRFFQPWGLWLRSSGLLFATFLLLSLFSLVASLLLVSHLYLVASNTTTWEFISSHRIAYLRQRPSNPFDRGLTRNLAHFFCGWPSGSWETLWAEEEEEGSSPAV |
| 分子量 | 62.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ZDHHC12蛋白的3篇假设性参考文献示例(注：文献为虚构，仅用于格式示范)：
---
1. **"Crystal structure of human ZDHHC12 palmitoyltransferase reveals substrate recognition mechanism"**
*Authors: Zhang Y, Wang L, Xu J (2022)*
**摘要**: 本研究解析了重组人ZDHHC12蛋白的晶体结构，揭示了其锌指结构域与底物结合的关键位点，并证明其通过特定的活性口袋催化棕榈酰化反应。
2. **"Recombinant ZDHHC12 mediates palmitoylation of oncogenic Ras proteins in vitro"**
*Authors: Patel S, Kim H, Gonzalez R (2020)*
**摘要**: 利用重组表达的ZDHHC12蛋白，验证了其在体外对KRAS和NRAS蛋白的棕榈酰化修饰功能，表明其可能调控RAS信号通路活性。
3. **"Development of a fluorescence-based assay for high-throughput screening of ZDHHC12 inhibitors"**
*Authors: Müller C, Fischer T (2019)*
**摘要**: 基于重组ZDHHC12蛋白构建了一种新型荧光检测方法，用于筛选其酶活抑制剂，为针对ZDHHC12的疾病治疗研究提供工具。
---
**说明**：若需真实文献，建议通过PubMed/Google Scholar检索关键词如“recombinant ZDHHC12”、“ZDHHC12 palmitoylation”获取最新研究。部分相关研究可能集中于ZDHHC家族其他成员(如ZDHHC13/17)，需进一步筛选。
ZDHHC12 is a member of the zinc finger DHHC-type (ZDHHC) protein family, which catalyzes protein palmitoylation—a post-translational modification involving the attachment of palmitate to cysteine residues. This reversible process regulates protein trafficking, stability, and interactions. Structurally, ZDHHC12 contains a conserved DHHC motif embedded in a cysteine-rich domain, along with multiple transmembrane regions, localizing it primarily to the endoplasmic reticulum and Golgi apparatus. Functionally, it has been implicated in diverse cellular processes, including synaptic plasticity, lipid metabolism, and cancer progression. Studies suggest ZDHHC12 palmitoylates specific substrates like BCR-ABL1 fusion protein in leukemia, influencing oncogenic signaling. It also interacts with proteins involved in neurodegenerative diseases, such as huntingtin, hinting at roles in neuronal health. Dysregulation of ZDHHC12 has been linked to breast cancer, gliomas, and cognitive deficits in animal models. Despite its emerging importance, the full spectrum of its substrates and regulatory mechanisms remains unclear. Recent research focuses on its potential as a therapeutic target and biomarker, leveraging its substrate specificity in disease contexts. Challenges include elucidating tissue-specific functions and resolving structural details of its catalytic activity.
×
